NTLA Intellia Therapeutics Inc.

14.37
-0.26  -2%
Previous Close 14.63
Open 14.55
Price To Book 2.55
Market Cap 702,438,191
Shares 48,882,268
Volume 522,541
Short Ratio
Av. Daily Volume 668,450
Stock charts supplied by TradingView

NewsSee all news

  1. Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones

    On track to submit IND application for lead candidate, NTLA-2001 for transthyretin amyloidosis, in mid-2020 and dose first patients in 2H 2020Nominated NTLA-5001 for the treatment of acute myeloid leukemia as first

  2. Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

    CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and

  3. Intellia Therapeutics Announces Third Quarter 2019 Financial Results

    On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis Expects to nominate its first T cell receptor-directed engineered cell therapy

  4. Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

    First reported consecutive in vivo gene knockout and insertion achieves therapeutically relevant results in an alpha-1 antitrypsin deficiency mouse modelInserted highly active WT1-TCR into the endogenous TCR locus for

  5. Intellia Therapeutics to Present at October Healthcare Investor Conferences

    CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

IND filing mid-2020 with dosing to commence 2H 2020.
NTLA-2001
transthyretin amyloidosis (ATTR)

Latest News

  1. Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones

    On track to submit IND application for lead candidate, NTLA-2001 for transthyretin amyloidosis, in mid-2020 and dose first patients in 2H 2020Nominated NTLA-5001 for the treatment of acute myeloid leukemia as first

  2. Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

    CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and

  3. Intellia Therapeutics Announces Third Quarter 2019 Financial Results

    On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis Expects to nominate its first T cell receptor-directed engineered cell therapy

  4. Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

    First reported consecutive in vivo gene knockout and insertion achieves therapeutically relevant results in an alpha-1 antitrypsin deficiency mouse modelInserted highly active WT1-TCR into the endogenous TCR locus for

  5. Intellia Therapeutics to Present at October Healthcare Investor Conferences

    CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and

  6. Arbitration Decision Affirms Intellia Therapeutics' Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

    Interim Award concluded all technology in dispute was exclusively licensed to IntelliaParties must negotiate terms and payments to Intellia for Caribou's use of the chemically modified guide RNAs   CAMBRIDGE, Mass.,